Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors. - Wikidata - wikimedia - TriplyDB

Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.

Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.

http://www.wikidata.org/entity/Q33793562

about

A critical review on ramucirumab in the treatment of advanced urothelial cancer.

P2860

Q47787312-21D501E0-34FE-4650-A777-B2AAE7F8CCF5

P2860

Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.

http://www.wikidata.org/entity/Q33793562

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Phase I Dose-Escalation Study ...... ts with Advanced Solid Tumors.

@ast

Phase I Dose-Escalation Study ...... ts with Advanced Solid Tumors.

@en

type

label

Phase I Dose-Escalation Study ...... ts with Advanced Solid Tumors.

@ast

Phase I Dose-Escalation Study ...... ts with Advanced Solid Tumors.

@en

prefLabel

Phase I Dose-Escalation Study ...... ts with Advanced Solid Tumors.

@ast

Phase I Dose-Escalation Study ...... ts with Advanced Solid Tumors.

@en

P1433

Q33793562-0F6D01D5-DC6E-468C-9B2D-EA59EFEC2777

P1476

Q33793562-93E5FD6D-8C04-4CD3-829A-997183FED4B1

P2093

Q33793562-01B89A86-CA57-4556-B800-41104D60F3C2

Q33793562-064E7F49-9946-46C3-9FA1-855F8849150A

Q33793562-50A64380-BA86-4B20-8B30-837582365A13

Q33793562-6A2E1537-8352-46C8-9316-EA9FDAA657EF

Q33793562-918D4BC2-038B-48A4-A4A5-358C4D022719

Q33793562-9464EBF0-2A7C-4C22-80E6-E6C4266BFC10

Q33793562-99594685-0C19-4CC4-B00F-1763584E6480

Q33793562-C0A72A15-6665-478C-A388-0C977C55DF66

Q33793562-DCD74C66-40DE-4084-B4B9-C33FD1FB0B21

Q33793562-E2A29802-0EC6-4CA1-8BAF-FD14FA008EB6

P2860

Q33793562-048AB093-7B4C-4BCE-94C6-CE8FCD77D855

Q33793562-215C5D6A-949D-494D-BE92-235D67DBD9C2

Q33793562-2C0A1B05-5176-44A5-A786-8A1D5B3DCF61

Q33793562-3CE00EC1-3571-43F1-BBCC-F64DF081CB2A

Q33793562-61FFA97E-6FE1-4C14-A688-4D16051AEEF6

Q33793562-6B62D5BE-6A56-4A1B-93DB-F57CC7B1C97E

Q33793562-97581C43-BE4D-4134-8C3F-CB48146F4B6B

Q33793562-9AADF3A5-31D6-4679-8785-DD7322E9275F

Q33793562-A9AEB9C2-93FF-482D-A1C6-BF7DAA62FF07

Q33793562-B85C831B-F433-45B9-B4FF-4D094671759E

P304

Q33793562-BAFC21C7-D25A-442C-8022-005069449F7B

P31

Q33793562-28372153-DB15-413C-AC78-707EAF33D023

P356

Q33793562-5391D8C2-5724-4ED8-B60A-0FF855FF6324

P433

Q33793562-4908B634-0410-47BA-96D7-22F307297995

P478

Q33793562-EB4F2D7E-8969-4AE6-B722-22CE041159B9

P577

Q33793562-341EBB7E-28BD-4455-AAF1-E2D4E043F7A2

P698

Q33793562-2CD09761-E932-4708-BC07-FA42829B9611

P932

Q33793562-391F364E-B52C-48B6-AF20-21AAD8636651

P356

THEONCOLOGIST.2017-0137

P1433

P1476

Phase I Dose-Escalation Study ...... ts with Advanced Solid Tumors.

@en

P2093

Amanda Long

http://www.w3.org/2001/XMLSchema#string

Baoyue Li

http://www.w3.org/2001/XMLSchema#string

Dongmei Ji

http://www.w3.org/2001/XMLSchema#string

Haidong Chi

http://www.w3.org/2001/XMLSchema#string

Jin Li

http://www.w3.org/2001/XMLSchema#string

Jin Wang

http://www.w3.org/2001/XMLSchema#string

Junning Cao

http://www.w3.org/2001/XMLSchema#string

Ling Gao

http://www.w3.org/2001/XMLSchema#string

Weina Shen

http://www.w3.org/2001/XMLSchema#string

Zhiyu Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

The VEGF family in cancer and antibody-based strategies for their inhibition.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

P304

638-e56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2017-0137

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28465370

http://www.w3.org/2001/XMLSchema#string

P932

5469595

http://www.w3.org/2001/XMLSchema#string